Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.

Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ.

Eur J Cancer. 2019 Jan;107:100-114. doi: 10.1016/j.ejca.2018.11.019. Epub 2018 Dec 14.

PMID:
30554073
2.

Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Heintges T, Kahl C, Kullmann F, Scheithauer W, Moehler M, Jelas I, Modest DP, Westphalen CB, von Einem JC, Michl M, Heinemann V.

Eur J Cancer. 2019 Jan;106:115-125. doi: 10.1016/j.ejca.2018.10.001. Epub 2018 Nov 27.

PMID:
30496943
3.

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.

Stintzing S, Ivanova B, Ricard I, Jung A, Kirchner T, Tannapfel A, Juette H, Hegewisch-Becker S, Arnold D, Reinacher-Schick A.

Front Oncol. 2018 Nov 8;8:474. doi: 10.3389/fonc.2018.00474. eCollection 2018.

4.

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).

Modest DP, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Peveling Genannt Reddemann C, Graeven U, Schuch G, Schwaner I, Stahler A, Jung A, Kirchner T, Held S, Stintzing S, Giessen-Jung C, Heinemann V; XELAVIRI/AIO KRK0110 Investigators.

J Clin Oncol. 2019 Jan 1;37(1):22-32. doi: 10.1200/JCO.18.00052. Epub 2018 Nov 2.

PMID:
30388045
5.

Recent advances in understanding colorectal cancer.

Stintzing S.

F1000Res. 2018 Sep 24;7. pii: F1000 Faculty Rev-1528. doi: 10.12688/f1000research.14604.1. eCollection 2018. Review.

6.

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.

Tokunaga R, Cao S, Naseem M, Lo JH, Battaglin F, Puccini A, Berger MD, Soni S, Millstein J, Zhang W, Stintzing S, Loupakis F, Cremolini C, Heinemann V, Falcone A, Lenz HJ.

Clin Colorectal Cancer. 2018 Sep 13. pii: S1533-0028(18)30387-6. doi: 10.1016/j.clcc.2018.09.003. [Epub ahead of print]

PMID:
30293873
7.

Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.

Laurent-Puig P, Grisoni ML, Heinemann V, Liebaert F, Neureiter D, Jung A, Montestruc F, Gaston-Mathe Y, Thiébaut R, Stintzing S.

Clin Cancer Res. 2019 Jan 1;25(1):134-141. doi: 10.1158/1078-0432.CCR-18-1324. Epub 2018 Aug 14.

PMID:
30108104
8.

The DNA-polymorphism rs849142 is associated with skin toxicity induced by targeted anti-EGFR therapy using cetuximab.

Froelich MF, Stintzing S, Kumbrink J, Grünewald TGP, Mansmann U, Heinemann V, Kirchner T, Jung A.

Oncotarget. 2018 Jul 13;9(54):30279-30288. doi: 10.18632/oncotarget.25689. eCollection 2018 Jul 13.

9.

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ.

Pharmacogenomics J. 2018 Sep;18(5):623-632. doi: 10.1038/s41397-018-0030-8. Epub 2018 Jun 21.

10.

Novel Common Genetic Susceptibility Loci for Colorectal Cancer.

Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C, Melas M, Van Den Berg DJ, Wang H, Tring S, Plummer SJ, Albanes D, Alonso MH, Amos CI, Anton K, Aragaki AK, Arndt V, Barry EL, Berndt SI, Bezieau S, Bien S, Bloomer A, Boehm J, Boutron-Ruault MC, Brenner H, Brezina S, Buchanan DD, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castelao JE, Chan AT, Chang-Claude J, Chanock SJ, Cheng I, Cheng YW, Chin LS, Church JM, Church T, Coetzee GA, Cotterchio M, Cruz Correa M, Curtis KR, Duggan D, Easton DF, English D, Feskens EJM, Fischer R, FitzGerald LM, Fortini BK, Fritsche LG, Fuchs CS, Gago-Dominguez M, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Giovannucci EL, Gogarten SM, Gonzalez-Villalpando C, Gonzalez-Villalpando EM, Grady WM, Greenson JK, Gsur A, Gunter M, Haiman CA, Hampe J, Harlid S, Harju JF, Hayes RB, Hofer P, Hoffmeister M, Hopper JL, Huang SC, Huerta JM, Hudson TJ, Hunter DJ, Idos GE, Iwasaki M, Jackson RD, Jacobs EJ, Jee SH, Jenkins MA, Jia WH, Jiao S, Joshi AD, Kolonel LN, Kono S, Kooperberg C, Krogh V, Kuehn T, Küry S, LaCroix A, Laurie CA, Lejbkowicz F, Lemire M, Lenz HJ, Levine D, Li CI, Li L, Lieb W, Lin Y, Lindor NM, Liu YR, Loupakis F, Lu Y, Luh F, Ma J, Mancao C, Manion FJ, Markowitz SD, Martin V, Matsuda K, Matsuo K, McDonnell KJ, McNeil CE, Milne R, Molina AJ, Mukherjee B, Murphy N, Newcomb PA, Offit K, Omichessan H, Palli D, Cotoré JPP, Pérez-Mayoral J, Pharoah PD, Potter JD, Qu C, Raskin L, Rennert G, Rennert HS, Riggs BM, Schafmayer C, Schoen RE, Sellers TA, Seminara D, Severi G, Shi W, Shibata D, Shu XO, Siegel EM, Slattery ML, Southey M, Stadler ZK, Stern MC, Stintzing S, Taverna D, Thibodeau SN, Thomas DC, Trichopoulou A, Tsugane S, Ulrich CM, van Duijnhoven FJB, van Guelpan B, Vijai J, Virtamo J, Weinstein SJ, White E, Win AK, Wolk A, Woods M, Wu AH, Wu K, Xiang YB, Yen Y, Zanke BW, Zeng YX, Zhang B, Zubair N, Kweon SS, Figueiredo JC, Zheng W, Marchand LL, Lindblom A, Moreno V, Peters U, Casey G, Hsu L, Conti DV, Gruber SB.

J Natl Cancer Inst. 2018 Jun 16. doi: 10.1093/jnci/djy099. [Epub ahead of print]

PMID:
29917119
11.

CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.

Froelich MF, Heinemann V, Sommer WH, Holch JW, Schoeppe F, Hesse N, Baumann AB, Kunz WG, Reiser MF, Ricke J, D'Anastasi M, Stintzing S, Modest DP, Kazmierczak PM, Hofmann FO.

Eur Radiol. 2018 Jun 7. doi: 10.1007/s00330-018-5454-7. [Epub ahead of print]

PMID:
29882070
12.

Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.

McSkane M, Stintzing S, Heinemann V, Puccini A, Naseem M, Cao S, Lenz HJ, Jelas I.

Clin Colorectal Cancer. 2018 Sep;17(3):215-222.e3. doi: 10.1016/j.clcc.2018.05.003. Epub 2018 May 10.

PMID:
29880436
13.

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer.

Goldberg RM, Montagut C, Wainberg ZA, Ronga P, Audhuy F, Taieb J, Stintzing S, Siena S, Santini D.

ESMO Open. 2018 May 5;3(4):e000353. doi: 10.1136/esmoopen-2018-000353. eCollection 2018. Review.

14.

Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases.

Winter KS, Hofmann FO, Thierfelder KM, Holch JW, Hesse N, Baumann AB, Modest DP, Stintzing S, Heinemann V, Ricke J, Sommer WH, D'Anastasi M.

Eur Radiol. 2018 May 7. doi: 10.1007/s00330-018-5424-0. [Epub ahead of print]

PMID:
29736851
15.

The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.

Neumann J, Heinemann V, Engel J, Kirchner T, Stintzing S.

Virchows Arch. 2018 Aug;473(2):199-207. doi: 10.1007/s00428-018-2360-y. Epub 2018 Apr 19.

PMID:
29675807
16.

Long-term Survival in Patients Treated with a Robotic Radiosurgical Device for Liver Metastases.

Stintzing S, Einem JV, Fueweger C, Haidenberger A, Fedorov M, Muavcevic A.

Cancer Res Treat. 2019 Jan;51(1):187-193. doi: 10.4143/crt.2017.594. Epub 2018 Apr 16.

17.

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.

Schirripa M, Zhang W, Yang D, Cao S, Okazaki S, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Alberti G, West JD, Lonardi S, Khoukaz T, Bergamo F, Battaglin F, Antoniotti C, Falcone A, Stintzing S, Heinemann V, Lenz HJ.

PLoS One. 2018 Mar 9;13(3):e0193640. doi: 10.1371/journal.pone.0193640. eCollection 2018.

18.

Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.

Hofmann FO, Holch JW, Heinemann V, Ricard I, Reiser MF, Baumann AB, Hesse N, D'Anastasi M, Modest DP, Stintzing S, Sommer WH.

Eur J Radiol. 2018 Mar;100:124-129. doi: 10.1016/j.ejrad.2018.01.006. Epub 2018 Jan 6.

PMID:
29496069
19.

Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Holch JW, von Einem JC, Held S, Heinemann V.

Oncotarget. 2017 Nov 11;8(62):105749-105760. doi: 10.18632/oncotarget.22396. eCollection 2017 Dec 1.

20.

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.

Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ.

Clin Cancer Res. 2018 Feb 15;24(4):784-793. doi: 10.1158/1078-0432.CCR-17-1663. Epub 2017 Dec 5.

PMID:
29208668
21.

[Personalized Treatment for Colorectal Carcinomas].

Stintzing S.

Dtsch Med Wochenschr. 2017 Nov;142(22):1652-1659. doi: 10.1055/s-0043-108467. Epub 2017 Oct 27. German.

PMID:
29078210
22.

Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.

Holch JW, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Kullmann F, Scheithauer W, Scholz M, Müller S, Link H, Rost A, Höffkes HG, Moehler M, Lindig RU, Miller-Phillips L, Kirchner T, Jung A, von Einem JC, Modest DP, Heinemann V.

Int J Cancer. 2018 Mar 1;142(5):1047-1055. doi: 10.1002/ijc.31114. Epub 2017 Nov 7.

PMID:
29047142
23.

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.

Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ.

Ann Oncol. 2017 Nov 1;28(11):2780-2785. doi: 10.1093/annonc/mdx412.

24.

Multidisciplinary treatment of colorectal liver metastases.

Schiergens TS, von Einem J, Thomas MN, Albertsmeier M, Giessen-Jung C, Dörsch M, Heiliger C, Drefs M, Andrassy J, Modest DP, Stintzing S, Guba M, Angele M, Werner J, Rentsch M.

Minerva Med. 2017 Dec;108(6):527-546. doi: 10.23736/S0026-4806.17.05371-X. Epub 2017 Sep 8. Review.

PMID:
28889727
25.

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).

Modest DP, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Moehler M, Westphalen CB, Holch JW, von Einem JC, Held S, Heinemann V; for FIRE-3/AIOKRK0306-investigators.

Eur J Cancer. 2017 Oct;84:262-269. doi: 10.1016/j.ejca.2017.07.030. Epub 2017 Aug 23.

PMID:
28843184
26.

Synchronous colorectal liver metastases: focus on the elderly : An Effectiveness Study from Routine Care.

Albertsmeier M, Engel A, Guba MO, Stintzing S, Schiergens TS, Schubert-Fritschle G, Hölzel D, Werner J, Angele MK, Engel J.

Langenbecks Arch Surg. 2017 Dec;402(8):1223-1232. doi: 10.1007/s00423-017-1611-8. Epub 2017 Aug 12.

PMID:
28803383
27.

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes.

Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ.

Eur J Cancer. 2017 Oct;84:69-80. doi: 10.1016/j.ejca.2017.07.016. Epub 2017 Aug 5. Review.

28.

Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.

Stahler A, Heinemann V, Neumann J, Crispin A, Schalhorn A, Stintzing S, Giessen-Jung C, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Quietzsch D, Holch JW, Kruger S, Haas M, Michl M, von Einem J, Kirchner T, Jung A, Modest DP.

Anticancer Drugs. 2017 Aug;28(7):717-722. doi: 10.1097/CAD.0000000000000510.

PMID:
28582279
29.

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.

Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ.

Int J Cancer. 2017 Sep 15;141(6):1222-1230. doi: 10.1002/ijc.30810. Epub 2017 Jun 21.

30.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 Investigators.

Eur J Cancer. 2017 Jul;79:50-60. doi: 10.1016/j.ejca.2017.03.023. Epub 2017 Apr 29.

PMID:
28463756
31.

Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.

Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ.

Pharmacogenomics J. 2018 Apr;18(2):262-269. doi: 10.1038/tpj.2017.9. Epub 2017 Apr 11.

PMID:
28398355
32.

Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.

Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ.

Int J Cancer. 2017 Jul 15;141(2):383-392. doi: 10.1002/ijc.30715. Epub 2017 May 10.

33.

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ.

Eur J Cancer. 2017 May;77:13-20. doi: 10.1016/j.ejca.2017.02.020. Epub 2017 Mar 26.

PMID:
28347919
34.

Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).

Modest DP, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Scheithauer W, Kirchner T, Jung A, Stauch M, von Einem JC, Moehler M, Held S, Heinemann V; FIRE-3 study investigators.

Int J Cancer. 2017 Apr 15;140(8):1918-1925. doi: 10.1002/ijc.30592. Epub 2017 Feb 8.

35.

A still missing piece of the FIRE-3 puzzle - Authors' reply.

Stintzing S, Heinemann V.

Lancet Oncol. 2016 Dec;17(12):e516. doi: 10.1016/S1470-2045(16)30597-6. No abstract available.

PMID:
27924747
36.

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials.

Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V.

Eur J Cancer. 2017 Jan;70:87-98. doi: 10.1016/j.ejca.2016.10.007. Epub 2016 Nov 29.

PMID:
27907852
37.

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V.

JAMA Oncol. 2016 Oct 10. doi: 10.1001/jamaoncol.2016.3797. [Epub ahead of print]

PMID:
27722750
38.

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.

Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.

Pharmacogenomics J. 2018 Jan;18(1):43-48. doi: 10.1038/tpj.2016.69. Epub 2016 Oct 4.

39.

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.

Heinemann V, Rivera F, O'Neil BH, Stintzing S, Koukakis R, Terwey JH, Douillard JY.

Eur J Cancer. 2016 Nov;67:11-20. doi: 10.1016/j.ejca.2016.07.019. Epub 2016 Sep 1.

40.

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.

Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators.

Lancet Oncol. 2016 Oct;17(10):1426-1434. doi: 10.1016/S1470-2045(16)30269-8. Epub 2016 Aug 27. Erratum in: Lancet Oncol. 2016 Oct;17 (10 ):e420. Lancet Oncol. 2016 Nov;17 (11):e479.

PMID:
27575024
41.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2017 Dec;17(6):543-550. doi: 10.1038/tpj.2016.59. Epub 2016 Aug 9.

PMID:
27503580
42.

Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives.

Holch J, Stintzing S, Heinemann V.

Visc Med. 2016 Jun;32(3):178-83. doi: 10.1159/000446052. Epub 2016 Jun 7. Review.

43.

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A.

Ann Oncol. 2016 Sep;27(9):1746-53. doi: 10.1093/annonc/mdw261. Epub 2016 Jun 29.

44.

CyberKnife Radiosurgery - Value as an Adjunct to Surgical Treatment of HCC?

Schoenberg M, Khandoga A, Stintzing S, Trumm C, Schiergens TS, Angele M, Op den Winkel M, Werner J, Muacevic A, Rentsch M.

Cureus. 2016 Apr 28;8(4):e591. doi: 10.7759/cureus.591.

45.

Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.

Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ.

Pharmacogenomics J. 2017 Dec;17(6):528-534. doi: 10.1038/tpj.2016.46. Epub 2016 May 31.

PMID:
27241062
46.

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).

Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Lerch MM, Modest DP, Kirchner T, Jung A, Heinemann V; FIRE-3 Study Group.

Ann Oncol. 2016 Aug;27(8):1565-72. doi: 10.1093/annonc/mdw222. Epub 2016 May 27.

PMID:
27234640
47.

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.

Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ.

Mol Cancer Ther. 2016 Jul;15(7):1740-5. doi: 10.1158/1535-7163.MCT-15-0931. Epub 2016 May 11.

48.

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.

Sunakawa Y, Bekaii-Saab T, Stintzing S.

Cancer Treat Rev. 2016 Apr;45:97-104. doi: 10.1016/j.ctrv.2016.03.007. Epub 2016 Mar 14. Review.

PMID:
27002945
49.

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.

Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ.

Clin Cancer Res. 2016 Jul 1;22(13):3218-26. doi: 10.1158/1078-0432.CCR-15-2422. Epub 2016 Feb 2.

50.

Genetic variants associated with colorectal brain metastases susceptibility and survival.

Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):29-35. doi: 10.1038/tpj.2015.86. Epub 2015 Dec 22.

PMID:
26689941

Supplemental Content

Loading ...
Support Center